News About: Pharm. Industry
Hanmi accepts USD 80 million upfront payment for technology transfer from Genentech
On the 25th of January, Hanmi Pharm made a notice that the company has accepted the USD 80 million upfront payment for the 2016’s technology transfer to Genentech and separate the amount into 30 months for the account...
‘Things to know’ about newly-adjusted pharma industry policies in 2017
While the cycle for drug price cuts will be adjusted from a year to 2 years from this year, punishment for drug rebates will be tightened.
Moreover, sellers of shortage-prevented drugs for less than 91% of their uppe...
KRPIA’s reappointment of Oak-Yeon Kim as Chair
The Korean Research-based Pharma Industry Association(KRPIA) announced on the 23rd that Oak-Yeon Kim was reappointed as the Chair of KRPIA for a year.
The reappointment of Chair Oak-Yeon Kim who served the associat...
Golden age of ‘middle-aged entertainment stars’ in drug advertisement
Middle-aged TV stars playing remarkable roles in TV shows have been selected as a commercial model for the pharmaceutical industry. It seems the industry prefers middle-aged entertainment TV stars over others because ...
Daewoong Pharmaceutical accelerates R&D with R&D troikaDaewoong Pharmaceutical will accelerate the process of global R&Ds by establishing a troika for the R&D field.
The troika are CEO/Vice Chairman Jong-Wook Lee, Vice President Bo...
|
Distribution industry, “We can’t rely on serial number data made by pharma companies”
Facing the obligation to report serial numbers of pharmaceutical product, pharmaceutical distribution companies are having difficulties from pharmaceutical companies’ errors.
Thus, pharmaceutical distribution compani...
Mundi Pharma signs co-sales agreement of ADHD therapy ‘Bisphentin’
Mundi Pharma(CEO Myung-Sae Lee) signed a co-sales agreement of ‘Bisphentin Controlled-Release Cap(generic name: methylphenidate hydrochloride),’ an attention-deficit/hyperactivity disorder(ADHD) therapy, with Korea Ph...
Green Cross-MSD’s strengthened bond in vaccine through co-promotion for ‘Gardasil’
On the 19th, Green Cross(CEO Eun-Cheol Huh) announced a co-promotion agreement of the MSD’s singles vaccine and cervical cancer, ‘Zostavax’ and ‘Gardasil & Gardasil 9,’ with MSD Korea on the 18th.
Under the agreement...
Dong Wha Pharm signs export agreement of USD 32 million for ‘Zabolante’
Dong Wha Pharm(Chairman Do-Joon Yoon) signed a license and supply agreement of the quinolone-type antibody ‘Zabolante,’ the Korea’s 23rd new drug, to commercialize in 12 countries, like the Middle East and North Afric...
Green Cross-MSD make explosive growth on ‘Zostavax’
‘Zostavax.’ a MSD’s shingles vaccine co-marketed by Green Cross, has shown an amazing uptrend.
According to the industry concerned, Zostavax has drawn a sharp rising curve with approximately KRW 80 billion sales incr...
